Michael Bretthauer, MD, PhD
President, Frontier Science Foundation
Michael Bretthauer, MD PhD, President, Frontier Science, Boston, USA is also a Professor of Medicine at the University of Oslo, a Gastroenterologist at Oslo University Hospital, and a Guest Researcher at Harvard School of Public Health. Throughout his distinguished career, Dr. Bretthauer has held many leadership, clinical, and research positions in Oslo, Norway, and in Boston, Massachusetts, US. He has been awarded numerous awards and honors, and has participated on many boards and committees. He is involved in editorial and teaching activities, and has an extensive list of publications. Dr. Bretthauer’s entire CV is available here.
Suzanne Siminski, MS, MBA
Chief Executive Officer, Frontier Science Foundation
Suzanne Siminski has been working in clinical trials data management and related research activities for more than 25 years. Sue has taken a leadership role in the development of Frontier Science’s laboratory data expertise and software. While Director of the New York office, Sue oversaw leadership groups involved in data management, software development, regulatory oversight and key projects. She currently serves as the Frontier Science Principal Investigator for PHACS and CPQA projects, and as co-Principal Investigator of the coordinating center for the C3PNO project, all programs funded by the NIH. As the Executive Director of Frontier Science Foundation, Sue is strategically increasing the repertoire of clinical research services provided by the organization, and actively building global collaborative partnerships with investigators around the world. Sue’s entire CV is available here.
Lisa Zdarsky, MBA
Chief Operating Officer, Frontier Science Foundation
Lisa Zdarsky earned her MBA from the State University of New York at Buffalo and has had extensive training in business and grants development. She has experience developing project concepts, project budgets, strategic plans and financial reports. Prior to assuming the position of COO in January 2018, Lisa held the role of Grant Administrator in the Frontier Science, Amherst, NY office.
Kathryn Gray, PhD
Director of Biostatistics and Office Director, Boston, Massachusetts
Dr. Kathryn P. Gray joined Frontier Science Foundation as Director of Biostatistics and Boston Office Director on March 1, 2019. Kathryn has been working in collaborative cancer clinical research, with the focus on gynecologic, breast, renal and prostate cancers, since 2010. She enjoys collaborating with investigators from multiple disciplines on clinical trial and translational studies with the goal of developing personalized cancer treatments. She has been the primary statistician for Dana Farber Cancer Institute’s (DFCI) Gynecologic Oncology Program providing statistical support and guidance for mostly phase I-II clinical trials that test new treatments for gynecologic cancer, including those targeting DNA repair, immunotherapy, antibody drug conjugates, and anti-angiogenesis agents, as well as trials studying strategies to overcome drug resistance. Kathryn is a member of the National Cancer Institute’s Gynecologic Cancers Steering Committee (GCSC), is also a senior statistician with the International Breast Cancer Study Group (IBCSG). Prior to working at DFCI, Kathryn worked with the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group.
Marlene Cooper, MS
Director of the Amherst, New York Office
Marlene Cooper has been involved in clinical trials data management and related research for more than 20 years. As the Director of the AIDS Clinical Trials Group (ACTG) and International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) projects at Frontier Science, Marlene is responsible for all Data Management Center (DMC) activities in support of these projects. As Director of the Amherst office for Frontier Science, Marlene continues to ensure that dedicated data management and core resources for programming, laboratory support, database operations and information technology are available for all projects. Marlene also serves as the Frontier Science Principal Investigator on several other NIH funded HIV/AIDS related research projects.
Jamie Hoel, MS
Director of the Madison, Wisconsin Office
Jamie Hoel has served as lead statistician and provided biostatistical support and direction in a wide range of disease areas, including but not limited to Relapsing Multiple Sclerosis, Secondary Hyperparathyroidism, Atrial Fibrillation, Atrial Flutter, Acute Decompensated Heart Failure, Dyslipidemia, Breast Cancer, Clostridium Difficile-Associated Diarrhea, Diabetes, Insomnia, Pulmonary Arterial Hypertension, and Menke’s Disease. In his extensive experience working with Data Monitoring Committees, Jamie has had the opportunity to work on a wide variety of different statistical analyses. Some of these include Nonparametric methods, Kaplan Meier estimates, futility analyses, conditional power calculations, O’Brien-Fleming monitoring boundaries, Inverse Probability of Censoring Weighting, and projections for event driven trials. Jamie Hoel joined Frontier Science in 2004 and served as a Biostatistician until 2015, when he was appointed as Associate Director of the Madison office. In 2018, he was appointed Director of the Madison office.
Eleanor McFadden, MS
Board Chair, Frontier Science Foundation; Managing Director, Frontier Science (Scotland) Ltd.
Eleanor McFadden has almost 40 years of experience in the management of clinical trials, including more than 20 years spent with Frontier Science Foundation in Boston, MA, US where she was Director of the Coordinating Center for the Eastern Cooperative Oncology Group. In 2000, Ms. McFadden returned to Great Britain to establish a Frontier Science office in in the Scottish Highlands. She has authored a book, Management of Data in Clinical Trials, and is a past President of the Society for Clinical Trials. Ms. McFadden received the Life Science Business Leadership prize at the 2015 Scottish Enterprise Life Sciences Awards. She has served on many review panels for various organisations such as the US National Cancer Institute, Cancer Research UK, the Irish Health Research Board and has been chair of the International Panel for the UK Clinical Research Network review and registration of UK Clinical Trials Units.
Urania Dafni, ScD
Director of Frontier Science Foundation-Hellas
Dr. Urania Dafni, Director of Frontier Science Foundation–Hellas (FSF-H) and Professor of Biostatistics at the University of Athens, is a founding member and served as President (2005-2007) of the Eastern Mediterranean Region of the International Biometric Society (IBS). Dr. Dafni was the Scientific Director of the National Syndromic Surveillance program for the Athens 2004 Olympic Games and is currently a member of the Board of Directors of the Hellenic Center for Disease Control and Prevention, Ministry of Health. She is a member of the Education committee of IBS, the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO), reflecting her over 25-year experience in Clinical trials.
Mette Kalager, MD, PhD
Chair of the Board of Frontier Science Norden
Dr. Kalager is a trained surgeon and is an associate professor at the University of Oslo, Norway. She is the head of the Clinical Effectiveness Research Group at the University of Oslo. She is a guest researcher at Harvard CH Chan School of Public Health and currently serves on the Scientific board of the French National Cancer Institute. Her research has a strong focus on clinical trials and epidemiology, including screening, surveillance, and studies in gastroenterology. She has a special interest in disseminating research to the general audience and has been on numerous radio programs including NPR and the Norwegian equivalent thereof, in the News (New York Times, Spiegel, Die Zeit). See Dr. Kalager’s professional page at the University of Oslo here. You can read more about Dr. Kalager at the Harvard School of Public Health website here.
Adel Ahmed, MS
Programming Division Chief
Adel Ahmed has extensive professional and leadership experience implementing software solutions and developing specialized applications that are tailored to clinical and laboratory research and compliant with applicable regulations. He oversees the programming division in the Amherst, NY office and is responsible for the data management IT software and applications. The programming division consists of several software engineering teams with a wide range of technical expertise dedicated to providing software services and innovative solutions to meet client needs. Adel has been with Frontier Science for two decades and serves on various leadership and steering committees. He graduated summa cum laude from the State University of New York at Buffalo with a BA and an MS in Computer Science and Engineering.
Peter Meszynski, MA
Peter Meszynski has been working in Information Technology at Frontier Science for over 20 years. Peter is committed to maintaining the ongoing stability of Frontier Science computer and communications systems by ensuring that Frontier Science computer systems meet the highest industry standards for data security and integrity. He is an accomplished IT leader with proven collaborative achievements, and has effectively led Frontier Science through several iterations of technical growth. Peter is a graduate of the State University of New York at Buffalo.
Lynette Blacher, MLS
Director of Data Management for the International Breast Cancer Study Group (IBCSG)
Lynette Blacher, Director of Data Management for the International Breast Cancer Study Group (IBCSG), has worked at Frontier Science for 20 years. Lynette is involved in global collaboration with research groups and networks in six continents to conduct clinical trials in breast cancer, and is responsible for oversight of all IBCSG data management and trial coordination activities within the Data Management Center (DMC) at Frontier Science. As a member of Frontier Science Leadership, Lynette is involved in several Frontier Science initiatives, including the State University of New York at Buffalo Intern Program, grant proposal writing, and the development of monitoring procedures. She is also a member of the Federal Information Security Management Act (FISMA) Group and Compliance Committee and coordinates the Cancer Projects Oversight Group.
Chief Financial Officer
Diana Sabra is the Frontier Science Chief Financial Officer and works in the Boston, MA office overseeing the accounting department. Diana has an extensive background in non-for-profit organizations for over 10 years. Prior to joining Frontier, she worked in public accounting as an auditor where she performed financial and compliance audits, reviews, compilations, and consulting services to clients, primarily in the non profit sector. She has made significant contributions within the accounting department at Frontier Science.
Board of Directors
- Eleanor McFadden, Board Chair
- Michael Bretthaeur, President
- Gregory Pavlov, Treasurer
- Hans-Olov Adami
- Urania Dafni
- David DeMets
- Richard Gelber
- Lawrence Huffman
- Mary Long
- Frank Rockhold
- Thelma Zelen